Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | SCN1A | P35498 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6195663 | 0.85 | HRH3 (0.61) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL5214308 | 0.84 | HRH3 (0.72) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL9530115 | 0.83 | ALDH1A1 (0.81) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL13949485 | 0.82 | EPHX2 (0.67) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL1242965 | 0.82 | HRH3 (0.70) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL29973108 | 0.81 | HRH3 (0.69) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL1244065 | 0.81 | HRH3 (0.69) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL63569 | 0.80 | SMN1; SMN2 (0.72) | HRH3ALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL23291210 | 0.79 | HRH3 (0.53) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 | |
| SCHEMBL14058776 | 0.79 | HRH3 (0.73) | HRH3ALDH1A1MAPK1CYP1A2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079503-A1 | Thiazolidinones and the use therof as polo-like kinase inhibitors | SCHERING AKTIENGESELLSCHAFT | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079503-A1 | Thiazolidinones and the use therof as polo-like kinase inhibitors | PLK4, PLK2, PLK3 | HRH3 3944/4885ALDH1A1 2553/4885MAPK1 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.